Meeting
2017 ASCO Annual Meeting
A phase II, open-label, randomized study to evaluate the efficacy and safety of GS-5745 combined with nivolumab versus nivolumab alone in subjects with unresectable or recurrent gastric or gastroesophageal junction adenocarcinoma.
Authors
Manish A. Shah
Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY
Manish A. Shah , Jean-Philippe Metges , Patrick Youngwhan Chun , Victoria Smith , Julia D. Maltzman , Zev A. Wainberg
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
NCT02864381
Citation
J Clin Oncol 35, 2017 (suppl; abstr TPS4141)
DOI
10.1200/JCO.2017.35.15_suppl.TPS4141
Abstract #
TPS4141
Poster Bd #
128a
Abstract Disclosures
Similar Posters
Poster
2019 Gastrointestinal Cancers Symposium
A phase II, open-label, randomized study to evaluate the efficacy and safety of andecaliximab combined with nivolumab versus nivolumab alone in subjects with unresectable or recurrent gastric or gastroesophageal junction adenocarcinoma.
First Author: Manish A. Shah
Poster
2017 ASCO Annual Meeting
An open-label, multicohort, phase I/II study to evaluate nivolumab in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC).
First Author: Jean-Pierre Delord
First Author: Igor Tsaur